Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
Molecular Pharmaceutics · 03.06.2024 · 21 (6) · 3053-3060
DOI: 10.1021/acs.molpharmaceut.4c00278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.05.2024. Verfasst von Yue Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aur…. Hauptthemen laut MEDLINE: Doxorubicin, Enzyme-Linked Immunosorbent Assay, Immunoglobulin G, Immunoglobulin M. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045-2559, United States.
- Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045-2559, United States.
- Department of Emergency Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045-2559, United States.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, Colorado 80045-2559, United States.
- School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU , U.K.
- Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, U.K.
ORCID-Profile: S Moein Moghimi, Dmitri Simberg
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Li, Y., Ettah, U., Jacques, S., Gaikwad, H., Monte, A., Dylla, L., Guntupalli, S., Moghimi, S. M., & Simberg, D. (2024). Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics, 21(6), 3053-3060. https://doi.org/10.1021/acs.molpharmaceut.4c00278
Vancouver
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, et al. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics. 2024;21(6):3053-3060. doi:10.1021/acs.molpharmaceut.4c00278
BibTeX
@article{Li2024,
author = {Li, Yue and Ettah, Utibeabasi and Jacques, Sarah and Gaikwad, Hanmant and Monte, Andrew and Dylla, Layne and Guntupalli, Saketh and Moghimi, S Moein and Simberg, Dmitri},
title = {Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {6},
pages = {3053--3060},
doi = {10.1021/acs.molpharmaceut.4c00278}
}
EUVIMED